96 related articles for article (PubMed ID: 9950443)
1. Control of hypercalcaemia of parathyroid carcinoma by immunisation.
Bradwell AR; Harvey TC
Lancet; 1999 Jan; 353(9150):370-3. PubMed ID: 9950443
[TBL] [Abstract][Full Text] [Related]
2. First Japanese patient treated with parathyroid hormone peptide immunization for refractory hypercalcemia caused by metastatic parathyroid carcinoma.
Horie I; Ando T; Inokuchi N; Mihara Y; Miura S; Imaizumi M; Usa T; Kinoshita N; Sekine I; Kamihara S; Eguchi K
Endocr J; 2010; 57(4):287-92. PubMed ID: 20051648
[TBL] [Abstract][Full Text] [Related]
3. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma.
Betea D; Bradwell AR; Harvey TC; Mead GP; Schmidt-Gayk H; Ghaye B; Daly AF; Beckers A
J Clin Endocrinol Metab; 2004 Jul; 89(7):3413-20. PubMed ID: 15240624
[TBL] [Abstract][Full Text] [Related]
4. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery.
Räkel A; Brossard JH; Patenaude JV; Albert C; Nassif E; Cantor T; Rousseau L; D'Amour P
Clin Endocrinol (Oxf); 2005 Jun; 62(6):721-7. PubMed ID: 15943835
[TBL] [Abstract][Full Text] [Related]
5. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
6. Very low or undetectable intact parathyroid hormone levels in patients with surgically verified parathyroid adenomas.
Bhadada SK; Cardenas M; Bhansali A; Mittal BR; Behera A; Chanukya GV; Nahar U; Rao DS
Clin Endocrinol (Oxf); 2008 Sep; 69(3):382-5. PubMed ID: 18284640
[TBL] [Abstract][Full Text] [Related]
7. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic-therapeutic management of parathyroid carcinoma].
Sillero Sánchez A; Atienza Iglesias MA
An Med Interna; 2002 Dec; 19(12):644-8. PubMed ID: 12593036
[TBL] [Abstract][Full Text] [Related]
9. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism.
Caron P; Maiza JC; Renaud C; Cormier C; Barres BH; Souberbielle JC
Clin Endocrinol (Oxf); 2009 Apr; 70(4):533-8. PubMed ID: 18782355
[TBL] [Abstract][Full Text] [Related]
10. [Surgical therapy concept in primary hyperparathyroidism].
Rusterholz D; Müller W
Schweiz Med Wochenschr Suppl; 2000; 116():62S-65S. PubMed ID: 10780075
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation.
Caron P; Simonds WF; Maiza JC; Rubin M; Cantor T; Rousseau L; Bilezikian JP; Souberbielle JC; D'Amour P
Clin Endocrinol (Oxf); 2011 Jun; 74(6):694-8. PubMed ID: 21521290
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid carcinoma: Challenges in diagnosis and treatment.
Betea D; Potorac I; Beckers A
Ann Endocrinol (Paris); 2015 May; 76(2):169-77. PubMed ID: 25910997
[TBL] [Abstract][Full Text] [Related]
14. PTH-independent hypercalcaemia and non-melanoma skin cancer.
Nicolae I; Schipor S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):449-52. PubMed ID: 19778357
[TBL] [Abstract][Full Text] [Related]
15. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.
Papapoulos SE; Harinck HI; Bijvoet OL; Gleed JH; Fraher LJ; O'Riordan JL
Bone Miner; 1986 Feb; 1(1):69-78. PubMed ID: 3508718
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunotherapy induces antitumour response in parathyroid carcinoma and neuroendocrine pancreas carcinoma.
Schott M; Seissler J; Feldkamp J; von Schilling C; Scherbaum WA
Horm Metab Res; 1999 Dec; 31(12):662-4. PubMed ID: 10668919
[TBL] [Abstract][Full Text] [Related]
17. Unexpected prolonged extreme hypocalcaemia and an inadequate PTH response in a patient with metastatic breast carcinoma.
Bergkamp FJ; van Berkel AM; van der Linden PW; Gorgels JP
Neth J Med; 2003 Nov; 61(11):371-5. PubMed ID: 14768721
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism.
Malberti F; Surian M; Cosci P
Nephrol Dial Transplant; 1992; 7(8):822-8. PubMed ID: 1325615
[TBL] [Abstract][Full Text] [Related]
19. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab.
Karuppiah D; Thanabalasingham G; Shine B; Wang LM; Sadler GP; Karavitaki N; Grossman AB
Eur J Endocrinol; 2014 Jul; 171(1):K1-5. PubMed ID: 24743399
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism.
Järhult J
Breast Cancer; 2014 May; 21(3):379-81. PubMed ID: 21290264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
